Global Organ-on-Chip Market Size, Share, Trends and Forecast 2026-2036 | Set to Reach $2.5 Billion as Regulatory Acceptance and Animal Testing Alternatives Drive 22.2% CAGR
Dublin, Nov. 16, 2026 (GLOBE NEWSWIRE) -- "Organ-on-Chip Market - Global Forecast to 2036" has been added to ResearchAndMarkets.com's offering.
The global Organ-on-Chip market is projected to reach $2.5 billion by 2036, expanding at a CAGR of 22.2% from 2026 to 2036. Market growth is being driven by increasing demand for alternatives to animal testing, rising drug discovery R&D costs, and growing regulatory acceptance of microphysiological systems as preclinical evidence.
Favorable policy and funding developments are also creating substantial opportunities for Organ-on-Chip market participants. The FDA Modernization Act 2.0 removed the statutory requirement for animal-based safety and efficacy data, while expanding NIH investment continues to support tissue chip technologies. These developments, combined with demand for human-relevant preclinical models, are accelerating adoption across pharmaceutical research, biotechnology, toxicology, and disease modeling.
The report provides historical market data for 2025, estimated market data for 2026, and forecasts through 2036. It evaluates the market by organ type, type, product & service, technology, cell source, application, end user, and geography.
Key Segment Insights
Regional Organ-on-Chip Market Outlook
North America is expected to account for the largest share of the Organ-on-Chip market in 2026. Growth in the region is supported by leading technology developers, substantial NIH funding through the Tissue Chip for Drug Screening program, and a more direct regulatory pathway for incorporating Organ-on-Chip data into U.S. drug development submissions.
Asia-Pacific is projected to register the highest CAGR during 2026-2036. Key growth factors include expanding pharmaceutical and biotechnology R&D investment in China, Japan, South Korea, and India; strengthening academic expertise in microfluidics and tissue engineering; and increasing government support for advanced life sciences research infrastructure.
Competitive Landscape
Key companies operating in the Organ-on-Chip market include Emulate, Inc. (U.S.), MIMETAS B.V. (Netherlands), CN Bio Innovations Ltd. (U.K.), TissUse GmbH (Germany), InSphero AG (Switzerland), Nortis, Inc. (U.S.), AlveoliX AG (Switzerland), Hesperos, Inc. (U.S.), Kirkstall Ltd. (U.K.), Cherry Biotech (France), AIM Biotech Pte. Ltd. (Singapore), SynVivo, Inc. (U.S.), Quris-AI (Israel), and Altis Biosystems, Inc. (U.S.).
Key Questions Addressed in the Report
For more information about this report visit https://www.researchandmarkets.com/r/4g7ytn
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.